The Residual Cancer Burden Index As a Valid Prognostic Indicator in Breast Cancer After Neoadjuvant Chemotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Jan 3

PMID 38166846

Authors

Xin Xu

Wei Zhao

Cuicui Liu

Yongsheng Gao

Dawei Chen

Meng Wu

Chao Li

Xinzhao Wang

Xiang Song

Jinming Yu

Zhaoyun Liu

Zhiyong Yu

Affiliations

Soon will be listed here.

Abstract

Purpose: The residual cancer burden index (RCB) was proposed as a response evaluation criterion in breast cancer patients treated with Neoadjuvant Chemotherapy (NAC). This study evaluated the relevance of RCB with replase-free survival (RFS).

Methods: The clinical data of 254 breast cancer patients who received NAC between 2016 and 2020 were retrospectively collected. The relationship between clinicopathologic factors and RFS was evaluated using Cox proportional hazards regression models. RFS estimates were determined by Kaplan-Meier(K-M) analysis and compared using the log-rank test. Multivariate logistic regression analysis was used to evaluate the risk factors associated with RCB. Receiver operating characteristic (ROC) curves showed the potential of the RCB and MP grading systems as biomarkers for RFS.

Results: At a median follow-up of 52 months, 59 patients(23.23%) developed relapse. Multivariate Cox regression showed that older age (P = 0.022), high Pathologic T stage after NAC (P = 0.023) and a high RCB score(P = 0.003) were risk factors for relapse. The outcomes of the multivariate logistic analysis indicated that RCB 0 (pathologic complete response [pCR]) was associated with HER2-positive patients (P = 0.002) and triple-negative breast cancer (TNBC) patients (P = 0.013). In addition, the RCB and MP scoring systems served as prognostic markers for patients who received NAC, and their area under curves (AUCs) were 0.691 and 0.342, respectively.

Conclusion: These data suggest that RCB can be equally applied to predict RFS in Chinese patients with NAC. The application of RCB may help guide the selection of treatment strategies.

Citing Articles

IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.

Huang Z, Liu Y, Li S, Li Y, Wu Z, He H Breast Cancer Res Treat. 2025; .

PMID: 39954110 DOI: 10.1007/s10549-025-07645-2.

Emerging role of PANoptosis in kidney diseases: molecular mechanisms and therapeutic opportunities.

Hou Y, Feng Q, Wei C, Cao F, Liu D, Pan S Apoptosis. 2025; .

PMID: 39833634 DOI: 10.1007/s10495-024-02072-y.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.

Manna M, Gelmon K, Boileau J, Brezden-Masley C, Cao J, Jerzak K Curr Oncol. 2024; 31(11):6536-6567.

PMID: 39590115 PMC: 11593131. DOI: 10.3390/curroncol31110484.

Successful treatment of enormous locally advanced breast cancer through neoadjuvant chemotherapy and surgical intervention: a case report.

Sin T, Huang J, Nie L, Mao F, Shen S, Li Y Gland Surg. 2024; 13(6):1126-1136.

PMID: 39015700 PMC: 11247592. DOI: 10.21037/gs-24-92.

Combining Molecular and Traditional Prognostic Factors: A Holistic Approach to Breast Cancer Prognostication.

Moraru L, Mitranovici M, Moraru R, Voidazan S, Munteanu M, Georgescu R Diagnostics (Basel). 2024; 14(13).

PMID: 39001339 PMC: 11241232. DOI: 10.3390/diagnostics14131449.

References

Nair V, Valo S, Peltomaki P, Bajbouj K, Abdel-Rahman W . Oncogenic Potential of Bisphenol A and Common Environmental Contaminants in Human Mammary Epithelial Cells. Int J Mol Sci. 2020; 21(10). PMC: 7279350. DOI: 10.3390/ijms21103735. View

Yamada K, Nishimura T, Wakiya M, Satoh E, Fukuda T, Amaya K . Protein co-expression networks identified from HOT lesions of ER+HER2-Ki-67high luminal breast carcinomas. Sci Rep. 2021; 11(1):1705. PMC: 7814020. DOI: 10.1038/s41598-021-81509-9. View

Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F . A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2023; 29(17):3429-3437. PMC: 10472099. DOI: 10.1158/1078-0432.CCR-23-0480. View

Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke E . De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised,.... Lancet Oncol. 2022; 23(5):625-635. DOI: 10.1016/S1470-2045(22)00159-0. View

Vignoli A, Muraro E, Miolo G, Tenori L, Turano P, Di Gregorio E . Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy. Cancers (Basel). 2020; 12(2). PMC: 7072610. DOI: 10.3390/cancers12020314. View

Naidoo K, Parham D, Pinder S . An audit of residual cancer burden reproducibility in a UK context. Histopathology. 2016; 70(2):217-222. DOI: 10.1111/his.13054. View

Chou H, Kuo W, Yu C, Tsai H, Shen S, Chu C . Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomed J. 2019; 42(1):66-74. PMC: 6468039. DOI: 10.1016/j.bj.2018.10.007. View

Braunstein L, Taghian A, Niemierko A, Salama L, Capuco A, R Bellon J . Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 2016; 161(1):173-179. DOI: 10.1007/s10549-016-4031-5. View

Hesse E, Schroder S, Brandt D, Pamperin J, Saito H, Taipaleenmaki H . Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019; 5. PMC: 6538320. DOI: 10.1172/jci.insight.125543. View

10.

Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S . Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2019; 179(1):11-23. DOI: 10.1007/s10549-019-05437-z. View

11.

Haque W, Verma V, Hatch S, Klimberg V, Butler E, Teh B . Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018; 170(3):559-567. DOI: 10.1007/s10549-018-4801-3. View

12.

Nuvoli S, Galassi S, Gelo I, Rocchitta G, Fancellu A, Serra P . The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy. Oncol Rep. 2018; 39(5):2055-2062. PMC: 5928762. DOI: 10.3892/or.2018.6299. View

13.

Qiu P, Zhao R, Wang W, Sun X, Chen P, Liu Y . Internal Mammary Sentinel Lymph Node Biopsy in Clinically Axillary Lymph Node-Positive Breast Cancer: Diagnosis and Implications for Patient Management. Ann Surg Oncol. 2019; 27(2):375-383. PMC: 6949312. DOI: 10.1245/s10434-019-07705-0. View

14.

Liu C, Wang W, Meng X, Sun B, Cong Y, Liu J . Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients. Onco Targets Ther. 2018; 11:2131-2139. PMC: 5905531. DOI: 10.2147/OTT.S159481. View

15.

Suppan C, Posch F, Mueller H, Mischitz N, Steiner D, Klocker E . Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. Cancers (Basel). 2021; 13(10). PMC: 8161089. DOI: 10.3390/cancers13102492. View

16.

Li Y, Zhou Y, Mao F, Lin Y, Zhang X, Shen S . The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis. Front Oncol. 2020; 10:933. PMC: 7333530. DOI: 10.3389/fonc.2020.00933. View

17.

Granzier R, Ibrahim A, Primakov S, Samiei S, van Nijnatten T, de Boer M . MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study. Cancers (Basel). 2021; 13(10). PMC: 8157878. DOI: 10.3390/cancers13102447. View

18.

Shang Y, Wang Q, Li J, Liu H, Zhao Q, Huang X . Zirconia Nanoparticles Induce HeLa Cell Death Through Mitochondrial Apoptosis and Autophagy Pathways Mediated by ROS. Front Chem. 2021; 9:522708. PMC: 8007972. DOI: 10.3389/fchem.2021.522708. View

19.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R . Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017; 15(10):1216-1223. DOI: 10.6004/jnccn.2017.0158. View

20.

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View